

# BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN: L24233MP1985PLC002709

Registered Office: 11/12, Sector E Sanwer Road, Indore-452015 (M.P.)

Tel. 0731-2723016; Email id- bcplcompliance@gmail.com;

Website- www.biofilgroup.net; Fax: 0731-2723017

**Dated: 12<sup>th</sup> August, 2025**

To, The Secretary ( <b>DCS/Compliance</b> ), Corporate Relationship Department, <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001	To, The Secretary ( <b>Listing/Compliance</b> ), Corporate Relationship Department, <b>National Stock Exchange of India Limited</b> , Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Mumbai – 400051
--	--

**Subject: Continuous Disclosure of material events or information under sub-clause 7 of Para A of Part A of Schedule III of SEBI (LODR) Regulations, 2015 for re-appointment of Independent Directors of the Company.**

**Reference: Biofil Chemicals & Pharmaceuticals Limited (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014)**

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR Regulations”) with reference to the Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13<sup>th</sup> July, 2023 regarding continuous disclosure requirements for listed entities we are enclosing disclosure as required under sub-clause 7 of Para A of Part A of Schedule III, Upon the recommendations of the Nomination and Remuneration Committee, the re-appointment of Independent Directors for second and final term of five years, subject to approval of the shareholders of the Company at the ensuing 40<sup>th</sup> Annual General Meeting.

Disclosure & Brief Profile of Independent Directors are enclosed with this letter.

Further, aforesaid disclosure shall also be available on the website of the Company at [www.biofilgroup.net](http://www.biofilgroup.net) and shall also be submitted in XBRL mode within prescribed time limit.

The Meeting of the Board of Directors commenced at 04.00 P.M. and concluded at 05.50 P.M.

You are requested to take the above information on record.

Thanking you,

Yours Faithfully,

**FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED**

**APOORV JAIN**  
**COMPANY SECRETARY & COMPLIANCE OFFICER**  
**M. NO. A71739**

**Encl: Brief Profile of for re-appointment of Independent Directors.**

**CONTINUOUS DISCLOSURE UNDER SUB-PARA 7 OF PARA A OF PART A OF SCHEDULE III  
PURSUANT TO REGULATION 30 OF THE SEBI (LODR) REGULATIONS, 2015**

**RE-APPOINTMENT INDEPENDENT DIRECTORS OF THE COMPANY.**

<b>S. No.</b>	<b>Particulars</b>	<b>Mr. Ashok Kumar Ramawat (DIN: 08818263)</b>	<b>Mr. Satish Beohar DIN: 09220291</b>
1	reason for change viz. <del>appointment, re-appointment, resignation, removal, death or otherwise</del>	Based on the recommendations of Nomination and Remuneration committee, Board of Directors of the Company has approved re-appointment of Mr. Ashok Kumar Ramawat (DIN: 08818263) as Independent Director of the Company	Based on the recommendations of Nomination and Remuneration committee, Board of Directors of the Company has approved re-appointment of Mr. Satish Beohar (DIN: 09220291) as Independent Director of the Company.
2	Date of <del>appointment/</del> re-appointment / <del>cessation</del> (as applicable) and term of <del>appointment/</del> re-appointment	The Board at its meeting held on 12 <sup>th</sup> August, 2025, approved the re-appointment of Mr. Ashok Kumar Ramawat (DIN: 08818263) for second and final term of five years commencing from 25 <sup>th</sup> August, 2025 to 24 <sup>th</sup> August, 2030 subject to the approval of the members at the ensuing 40 <sup>th</sup> Annual General Meeting of the Company.	The Board at its meeting held on 12 <sup>th</sup> August, 2025, approved the re-appointment of Mr. Satish Beohar (DIN: 09220291) for second and final term of five years commencing from 30 <sup>th</sup> June, 2026 to 29 <sup>th</sup> June, 2031 subject to the approval of the members at the ensuing 40 <sup>th</sup> Annual General Meeting of the Company.
3	brief profile (in case of <del>Appointment-re-</del> appointment)	Mr. Ashok Kumar Ramawat has completed Bachelors Degree in Science.  He possess 45 years of post qualification experience and a good exposure in Pharmaceuticals Industry.	Mr. Satish Beohar has completed Masters Degree in Science  He Possess 35 years of post qualification experience and a good exposure in the field of Sales and Marketing.
4	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Ashok Kumar Ramawat is not related to any of the Directors of the Company.	Mr. Satish Beohar is not related to any of the Directors of the Company.

Further the Company would like to bring to your notice that SEBI Letter dated June 14, 2018 read along with Circular No. LIST/COMP/14/2018-19 and NSE/CML/2018/24 dated June 20, 2018 issued by BSE and NSE respectively, requires Listed Companies to ensure that the person proposed to be appointed as “Director” shall not be debarred from holding the office by virtue of any SEBI Order or any other authority.

We would like to confirm that Mr. Ashok Kumar Ramawat (DIN: 08818263) and Mr. Satish Beohar (DIN: 09220291) who have been re-appointed as Non-Executive Independent Directors of the company are not debarred from accessing the Capital Market and neither SEBI nor any authority had passed any order against them debarring from accessing the capital market.

**FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED**

**APOORV JAIN**  
**COMPANY SECRETARY & COMPLIANCE OFFICER**  
**M. NO. A71739**